Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20180813rdf:typepubmed:Citationlld:pubmed
pubmed-article:20180813lifeskim:mentionsumls-concept:C0038952lld:lifeskim
pubmed-article:20180813lifeskim:mentionsumls-concept:C0018270lld:lifeskim
pubmed-article:20180813lifeskim:mentionsumls-concept:C1999216lld:lifeskim
pubmed-article:20180813lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:20180813lifeskim:mentionsumls-concept:C2346875lld:lifeskim
pubmed-article:20180813pubmed:issue5lld:pubmed
pubmed-article:20180813pubmed:dateCreated2010-6-10lld:pubmed
pubmed-article:20180813pubmed:abstractTextAurora A kinase plays an essential role in the proper assembly and function of the mitotic spindle. We have shown previously that Aurora A expression is increased aberrantly in human T-cell leukemia virus type 1 (HTLV-1)-infected T-cell lines and primary adult T-cell leukemia cells, and a pan-Aurora kinase inhibitor, which inhibits both Aurora A and Aurora B kinases, reduces viability and induces apoptosis in these cells. However, the specific effects of Aurora A inhibition on HTLV-1-infected T-cells are poorly understood. In this study, we addressed this question by comparing the effects of MLN8237, a selective inhibitor of Aurora A, on cell viability, cell cycle progression, and induction of apoptosis in HTLV-1-infected and -uninfected T-cell lines. MLN8237 reduced the viability of HTLV-1-infected T-cell lines within 24 h, but its effects on that of HTLV-1-uninfected T-cell lines were moderate. MLN8237 induced early apoptosis of HTLV-1-infected T-cell lines without induction of polyploidy. It induced p53 and p21 expression in HTLV-1-infected but not in -uninfected T-cell lines, suggesting that MLN8237-treated HTLV-1-infected T-cell lines exit from mitosis and activate a p53-dependent postmitotic G(1) checkpoint, leading to G(1) arrest followed by the induction of apoptosis. Our results suggest that specific inhibition of Aurora A kinase is a potentially useful therapeutic strategy in the treatment of adult T-cell leukemia and that further in vivo exploration is warranted.lld:pubmed
pubmed-article:20180813pubmed:languageenglld:pubmed
pubmed-article:20180813pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20180813pubmed:citationSubsetIMlld:pubmed
pubmed-article:20180813pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20180813pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20180813pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20180813pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20180813pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20180813pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20180813pubmed:statusMEDLINElld:pubmed
pubmed-article:20180813pubmed:monthMaylld:pubmed
pubmed-article:20180813pubmed:issn1349-7006lld:pubmed
pubmed-article:20180813pubmed:authorpubmed-author:MoriNaokiNlld:pubmed
pubmed-article:20180813pubmed:authorpubmed-author:TomitaMarikoMlld:pubmed
pubmed-article:20180813pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20180813pubmed:volume101lld:pubmed
pubmed-article:20180813pubmed:ownerNLMlld:pubmed
pubmed-article:20180813pubmed:authorsCompleteYlld:pubmed
pubmed-article:20180813pubmed:pagination1204-11lld:pubmed
pubmed-article:20180813pubmed:dateRevised2011-7-11lld:pubmed
pubmed-article:20180813pubmed:meshHeadingpubmed-meshheading:20180813...lld:pubmed
pubmed-article:20180813pubmed:meshHeadingpubmed-meshheading:20180813...lld:pubmed
pubmed-article:20180813pubmed:meshHeadingpubmed-meshheading:20180813...lld:pubmed
pubmed-article:20180813pubmed:meshHeadingpubmed-meshheading:20180813...lld:pubmed
pubmed-article:20180813pubmed:meshHeadingpubmed-meshheading:20180813...lld:pubmed
pubmed-article:20180813pubmed:meshHeadingpubmed-meshheading:20180813...lld:pubmed
pubmed-article:20180813pubmed:meshHeadingpubmed-meshheading:20180813...lld:pubmed
pubmed-article:20180813pubmed:meshHeadingpubmed-meshheading:20180813...lld:pubmed
pubmed-article:20180813pubmed:meshHeadingpubmed-meshheading:20180813...lld:pubmed
pubmed-article:20180813pubmed:meshHeadingpubmed-meshheading:20180813...lld:pubmed
pubmed-article:20180813pubmed:year2010lld:pubmed
pubmed-article:20180813pubmed:articleTitleAurora A selective inhibitor MLN8237 suppresses the growth and survival of HTLV-1-infected T-cells in vitro.lld:pubmed
pubmed-article:20180813pubmed:affiliationDivision of Molecular Virology and Oncology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. mtomita@med.u-ryukyu.ac.jplld:pubmed
pubmed-article:20180813pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20180813pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed